<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFTAZIDIME- ceftazidimeÂ injection, powder, for solutionÂ </strong><br>WG Critical Care, LLC<br></p></div>
<h1>Ceftazidime for Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_table_id_5f3b1aea-ad8c-479f-b77d-0f026760adb7"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PHARMACY BULK PACKAGE</span></p>
<p><span class="Bold">NOT FOR DIRECT INFUSION</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4f12b72b-3c61-4f1f-ab41-2824c5663cfe"></a><a name="section-1"></a><p></p>
<p class="First">For Intravenous Use</p>
<p>Rx only</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection and other antibacterial drugs, ceftazidime for injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_e57f75d1-70bf-4053-898b-a70f9390c519"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Î±,7Î²(Z)]]. It has the following structural formula:</p>
<div class="Figure">
<a name="id216"></a><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=22d6534c-4488-48a1-8d78-e2fb908259de&amp;name=image-01.jpg">
</div>
<p>The molecular formula is C<span class="Sub">22</span>H<span class="Sub">32</span>N<span class="Sub">6</span>O<span class="Sub">12</span>S<span class="Sub">2</span>, representing a molecular weight of 636.6.</p>
<p>Ceftazidime for injection, USP is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. </p>
<p>Ceftazidime for injection, USP is a white to cream-colored crystalline powder. Solutions of ceftazidime for injection, USP range in color from light yellow to amber, depending on the diluent and volume used. The pH of freshly constituted solutions usually ranges from 5 to 8.</p>
<p>Ceftazidime for injecton, USP in sterile crystalline form is supplied in 6 gram Pharmacy Bulk Package bottles equivalent to 6 grams of anhydrous ceftazidime.</p>
<p>The Pharmacy Bulk Package bottle contains 708 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3 mEq) per gram of ceftazidime.</p>
<p>The 6 g Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE 6 g PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION. FURTHER DILUTION IS REQUIRED BEFORE USE.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_11edd41e-e7ad-454b-ae6b-901646cd9d16"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">After IV administration of 500 mg and 1 g doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum concentrations of 45 and 90 mcg/mL, respectively, were achieved. After IV infusion of 500 mg, 1 g, and 2 g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved. The average serum concentrations following IV infusion of 500 mg, 1 g, and 2 g doses to these volunteers over an 8-hour interval are given in <a href="#_RefIDD36496B237B945FCB22DA5BD038CCB4C">Table 1</a>.</p>
<a name="_RefIDD36496B237B945FCB22DA5BD038CCB4C"></a><table width="100%">
<caption><span>Table 1. Average Serum Concentrations of Ceftazidime </span></caption>
<col width="23%">
<col width="9%">
<col width="7%">
<col width="7%">
<col width="7%">
<col width="7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Ceftazidime IV Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Serum Concentrations (mcg/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">0.5 hr</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 hr</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 hr</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8 hr</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">500 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">42</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1 g</p></td>
<td class="Botrule Lrule" align="center"><p class="First">60</p></td>
<td class="Botrule Lrule" align="center"><p class="First">39</p></td>
<td class="Botrule Lrule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">2 g</p></td>
<td class="Botrule Lrule" align="center"><p class="First">129</p></td>
<td class="Botrule Lrule" align="center"><p class="First">75</p></td>
<td class="Botrule Lrule" align="center"><p class="First">42</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
</tr>
</tbody>
</table>
<p>The absorption and elimination of ceftazidime were directly proportional to the size of the dose. The half-life following IV administration was approximately 1.9 hours. Less than 10% of ceftazidime was protein bound. The degree of protein binding was independent of concentration. There was no evidence of accumulation of ceftazidime in the serum in individuals with normal renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days.</p>
<p>The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days. Therefore, a dosage adjustment from the normal recommended dosage is not required for patients with hepatic dysfunction, provided renal function is not impaired.</p>
<p>Approximately 80% to 90% of an IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. After the IV administration of single 500 mg or 1 g doses, approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later. The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine.</p>
<p>The mean renal clearance of ceftazidime was approximately 100 mL/min. The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the elimination kinetics of ceftazidime. This suggested that ceftazidime is eliminated by glomerular filtration and is not actively secreted by renal tubular mechanisms.</p>
<p>Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Consequently, dosage adjustments in such patients as described in the <span class="Bold"><a href="#i4i_dosage_admin_id_2a96dd57-bbfe-4d96-8576-af6ed0059c52">DOSAGE AND ADMINISTRATION</a>Â Â Â Â Â </span>section are suggested. </p>
<p>Therapeutic concentrations of ceftazidime are achieved in the following body tissues and fluids.</p>
<a name="_RefIDAF1552E94E484060A3C80D5CEA9523F7"></a><table width="100%">
<caption><span>Table 2. Ceftazidime Concentrations in Body Tissues and Fluids </span></caption>
<col width="20%">
<col width="12%">
<col width="15%">
<col width="24%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Tissue or Fluid</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Dose/</span></p>
<p><span class="Bold">Route</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">No. of Patients</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Time of Sample Postdose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Average Tissue or Fluid Level</span></p>
<p><span class="Bold">(mcg/mL or mcg/g)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Urine</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0 to 2 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12,000</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Bile</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">90 min</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">36.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Synovial fluid</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Peritoneal fluid</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">48.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Cerebrospinal fluid</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g q8hr IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">120 min</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">(inflamed meninges)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g q8hr IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">180 min</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Aqueous humor</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 to 3 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> fluid</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 to 3 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Lymphatic fluid</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 to 3 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Bone</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.67 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Heart muscle</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">35</p></td>
<td class="Botrule Lrule" align="center"><p class="First">30 to 280 min</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Skin</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule" align="center"><p class="First">30 to 180 min</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Skeletal muscle</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">35</p></td>
<td class="Botrule Lrule" align="center"><p class="First">30 to 280 min</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Myometrium</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 g IV</p></td>
<td class="Botrule Lrule" align="center"><p class="First">31</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 to 2 hr</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18.7</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_fb9f0669-06de-4dfa-bed1-d613b1052df1"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First"><span class="Bold"><span class="Italics">Mechanism of Action</span></span></p>
<p>Ceftazidime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftazidime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram positive bacteria. </p>
<p><span class="Bold"><span class="Italics">Mechanism of Resistance </span></span></p>
<p>Resistance to ceftazidime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability. </p>
<p>Interaction with Other Antimicrobials </p>
<p>In an in vitro study, antagonistic effects have been observed with the combination of chloramphenicol and ceftazidime. </p>
<p>Ceftazidime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section: </p>
<p>Gram-negative bacteria </p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Citrobacter </span>species </dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Enterobacter </span>species </dd>
<dt>â€¢</dt>
<dd><span class="Italics">Escherichia coli</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Klebsiella </span>species </dd>
<dt>â€¢</dt>
<dd><span class="Italics">Haemophilus influenzae </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Neisseria meningitidis </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Proteus mirabilis </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Proteus vulgaris </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Pseudomonas aeruginosa </span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Serratia </span>species </dd>
</dl>
<p>Gram-positive bacteria </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Italics">Staphylococcus aureus</span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Streptococcus pneumoniae</span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Streptococcus pyogenes </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Streptococcus agalactiae </span></dd>
</dl>
<p>Anaerobic bacteria </p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Bacteroides </span>species (Note: many isolates of <span class="Italics">Bacteroides </span>species are resistant)</dd>
</dl>
<p>The following <span class="Italics">in vitro </span>data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for ceftazidime. However, the efficacy of ceftazidime in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms has not been established in adequate and well-controlled clinical trials. </p>
<p>Gram-negative bacteria </p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Acinetobacter </span>species </dd>
<dt>â€¢</dt>
<dd><span class="Italics">Citrobacter diversus </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Citrobacter freundii </span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Providencia </span>species (including <span class="Italics">Providencia rettgeri</span>) </dd>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>species </dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Shigella </span>species </dd>
<dt>â€¢</dt>
<dd><span class="Italics">Haemophilus parainfluenzae </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Morganella morganii </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Neisseria gonorrhoeae </span></dd>
<dt>â€¢</dt>
<dd><span class="Italics">Yersinia enterocolitica </span></dd>
</dl>
<p>Gram-positive bacteria </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Italics">Staphylococcus epidermidis </span></dd>
</dl>
<p>Anaerobic bacteria </p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Clostridium </span>species (Not including <span class="Italics">Clostridium difficile) </span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Peptostreptococcus </span>species </dd>
</dl>
<p><span class="Bold"><span class="Italics">Susceptibility Test Methods </span></span></p>
<p>When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment. </p>
<p>Dilution techniques </p>
<p>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method <span class="Sup">1,2</span>. The MIC values should be interpreted according to criteria provided in <span class="Italics">Table 3.</span></p>
<p>Diffusion techniques </p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method <span class="Sup">2,3</span>. This procedure uses paper disks impregnated with 30 mcg ceftazidime to test the susceptibility of microorganisms to ceftazidime. The disk diffusion interpretive criteria are provided in <span class="Italics">Table 3. </span></p>
<p><span class="Bold">Table 3. Susceptibility Test Interpretive Criteria for Ceftazidime</span></p>
<table width="459.05pt">
<col width="23%">
<col width="12%">
<col width="12%">
<col width="10%">
<col width="15%">
<col width="12%">
<col width="12%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><dl>
<dt>Â </dt>
<dd><span class="Bold">Pathogen </span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" colspan="3"><dl>
<dt>Â </dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/ml)</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Disk Diffusion Zone Diameters (mm)</span></p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">(S) Susceptible</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">(I) Intermediate</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">(R)</span></dd>
<dt>Â </dt>
<dd><span class="Bold">Resistant</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">(S) </span></dd>
<dt>Â </dt>
<dd><span class="Bold">Susceptible</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">(I)</span></dd>
<dt>Â </dt>
<dd><span class="Bold">Intermediate</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">(R)</span></dd>
<dt>Â </dt>
<dd><span class="Bold">Resistant</span></dd>
</dl></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>
<span class="Italics">Enterobacteriaceae</span><span class="Sup">Â§</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¤ 4</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>8</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¥ 16</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¥ 21</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>18 to 20</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¤ 17</dd>
</dl></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>
<span class="Italics">Haemophilus influenzae</span><span class="Sup">a</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¤ 2</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>-</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>-</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¥ 26</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>-</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>-</dd>
</dl></td>
</tr>
<tr class="Last Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Italics">Pseudomonas aeruginosa*</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¤ 8</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>-</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¥ 16</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¥ 18</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>-</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd>â‰¤ 17</dd>
</dl></td>
</tr>
</tbody>
</table>
<p>Â§ Susceptibility interpretive criteria for <span class="Italics">Enterobacteriaceae </span>are based on a dose of 1 gram q 8h. For isolates with intermediate susceptibility, use a dose of 2 grams every 8 hours in patients with normal renal function. </p>
<p>* For <span class="Italics">P. aeruginosa</span>, susceptibility interpretive criteria are based on a dose of 2 grams IV every 8 hours in patients with normal renal function. </p>
<p><span class="Sup">a </span>The current absence of data on resistant isolates precludes defining any category other than â€˜Susceptibleâ€™. If isolates yield MIC results other than susceptible, they should be submitted to a reference laboratory for additional testing. </p>
<p>Susceptibility of staphylococci to ceftazidime may be deduced from testing only penicillin and either cefoxitin or oxacillin.</p>
<p>A report of "Susceptible" indicates that the antimicrobial drug is likely to inhibit growth of the microorganism if the antimicrobial drug reaches the concentration usually achievable at the site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the antimicrobial is not likely to inhibit growth of the microorganism if the antimicrobial drug reaches the concentration usually achievable at the site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; other therapy should be selected. </p>
<p>Quality Control </p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test<span class="Sup">1,2,3,4</span>. Standard ceftazidime powder should provide the following range of MIC values noted in <span class="Italics">Table 4. </span>For the diffusion technique using the 30 mcg disk, the criteria in <span class="Italics">Table 4 </span>should be achieved.</p>
<p><span class="Bold">Table 4. Acceptable Quality Control Ranges for Ceftazidime</span></p>
<table width="383.2pt">
<col width="39%">
<col width="22%">
<col width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Bold">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL) </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Disk Diffusion Zone diameters (mm) </span></p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Escherichia coli </span>ATCC 25922 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.06 to 0.5 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25 to 32 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Staphylococcus aureus </span>ATCC 25923 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">---------</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16 to 20 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Staphylococcus aureus </span>ATCC 29213 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 to 16 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">---------</p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Haemophilus influenzae </span>ATCC 49247 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.12 to 1 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">27 to 35 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Neisseria gonorrhoeae </span>ATCC 49226 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.03 to 0.12 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">35 to 43 </p></td>
</tr>
<tr class="Last Toprule">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Pseudomonas aeruginosa </span>ATCC 27853<span class="Italics"></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 to 4 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22 to 29 </p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_6e320a0f-afce-4361-ae11-e282cd63bb2e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"> Ceftazidime for injection, USP is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the following diseases:</p>
<p><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span>, </span>including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, caused by <span class="Italics">Pseudomonas aeruginosa </span>and other <span class="Italics">Pseudomonas </span>spp.; <span class="Italics">Haemophilus influenzae, </span>including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>; <span class="Italics">Klebsiella </span>spp.; <span class="Italics">Enterobacter </span>spp.; <span class="Italics">Proteus mirabilis; Escherichia coli; Serratia </span>spp.; <span class="Italics">Citrobacter </span>spp.; <span class="Italics">Streptococcus pneumoniae; </span>and <span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
<p><span class="Bold">2. Skin and Skin-Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span>caused by <span class="Italics">Pseudomonas aeruginosa; Klebsiella </span>spp.; <span class="Italics">Escherichia coli; Proteus </span>spp., including <span class="Italics">Proteus mirabilis </span>and indole-positive <span class="Italics">Proteus; Enterobacter </span>spp.; <span class="Italics">Serratia </span>spp.; <span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>); and <span class="Italics">Streptococcus pyogenes </span>(group A beta-hemolytic streptococci).</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>, </span>both complicated and uncomplicated, caused by <span class="Italics">Pseudomonas aeruginosa; Enterobacter </span>spp.; <span class="Italics">Proteus </span>spp., including <span class="Italics">Proteus mirabilis </span>and indole-positive <span class="Italics">Proteus; Klebsiella </span>spp.; and <span class="Italics">Escherichia coli.</span></p>
<p><span class="Bold">4. Bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span> </span>caused by <span class="Italics">Pseudomonas aeruginosa, Klebsiella </span>spp., <span class="Italics">Haemophilus influenzae, Escherichia coli, Serratia </span>spp., <span class="Italics">Streptococcus pneumoniae, </span>and <span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
<p><span class="Bold">5. Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span> </span>caused by <span class="Italics">Pseudomonas aeruginosa, Klebsiella </span>spp., <span class="Italics">Enterobacter </span>spp., and <span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
<p><span class="Bold">6. Gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>, </span>including <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, pelvic <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the female genital tract caused by <span class="Italics">Escherichia coli.</span></p>
<p><span class="Bold">7. Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal Infections</span>, </span>including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> caused by <span class="Italics">Escherichia coli, Klebsiella </span>spp., and <span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) and polymicrobial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by aerobic and anaerobic organisms and <span class="Italics">Bacteroides </span>spp. (many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Bacteroides fragilis </span>are resistant).</p>
<p><span class="Bold">8. Central Nervous System <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>, </span>including <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, caused by <span class="Italics">Haemophilus influenzae </span>and <span class="Italics">Neisseria meningitidis. </span>Ceftazidime has also been used successfully in a limited number of cases of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> due to <span class="Italics">Pseudomonas aeruginosa </span>and <span class="Italics">Streptococcus pneumoniae.</span></p>
<p>Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used.</p>
<p>Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patientâ€™s condition.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_b150ffdf-9ab6-4296-aeac-d630c28901af"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ceftazidime for injection is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ceftazidime or the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_472c30aa-e7af-46e8-97bf-e0647a877d4f"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">BEFORE THERAPY WITH CEFTAZIDIME FOR INJECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFTAZIDIME, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFTAZIDIME FOR INJECTION OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. </p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ceftazidime for injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>. </p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p>Elevated levels of ceftazidime in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> can lead to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, and myoclonia (see <span class="Bold"><a href="#i4i_precautions_id_03beb54d-c169-4418-b5d9-8056a58671a1">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_03beb54d-c169-4418-b5d9-8056a58671a1"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_2fbe65d8-c0b1-456b-aaaf-05b85ebbae03"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">High and prolonged serum ceftazidime concentrations can occur from usual dosages in patients with transient or persistent reduction of urinary output because of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. The total daily dosage should be reduced when ceftazidime is administered to patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <span class="Bold"><a href="#i4i_dosage_admin_id_2a96dd57-bbfe-4d96-8576-af6ed0059c52">DOSAGE AND ADMINISTRATION</a></span>). Elevated levels of ceftazidime in these patients can lead to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, and myoclonia. Continued dosage should be determined by degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organisms.</p>
<p>As with other antibiotics, prolonged use of ceftazidime may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patientâ€™s condition is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken. </p>
<p>Inducible type I beta-lactamase resistance has been noted with some organisms (e.g., <span class="Italics">Enterobacter </span>spp., <span class="Italics">Pseudomonas </span>spp., and <span class="Italics">Serratia </span>spp.). As with other extended-spectrum beta-lactam antibiotics, resistance can develop during therapy, leading to clinical failure in some cases. When treating <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by these organisms, periodic susceptibility testing should be performed when clinically appropriate. If patients fail to respond to monotherapy, an aminoglycoside or similar agent should be considered.</p>
<p>Cephalosporins may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity. Those at risk include patients with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored in patients at risk and exogenous vitamin K administered as indicated.</p>
<p>Ceftazidime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. </p>
<p>Distal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> can occur after inadvertent intra-arterial administration of ceftazidime. </p>
<p>Prescribing ceftazidime for injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_58b2458d-9cc6-4d23-95a5-c94c98f6df05"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs, including ceftazidime for injection, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When ceftazidime for injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ceftazidime for injection or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_a9012104-1a7e-4c5f-b0cc-2e96dcc08507"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> of aminoglycoside antibiotics. <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> and <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> were not noted when ceftazidime was given alone in clinical trials. </p>
<p>Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli. Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided.</p>
<p>In common with other antibiotics, ceftazidime may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_45240799-1a56-46b0-890c-1e0749edc4d6"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">The administration of ceftazidime may result in a false-positive reaction for glucose in the urine when using CLINITESTÂ® tablets, Benedictâ€™s solution, or Fehlingâ€™s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIXÂ®) be used.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_658f6ea8-bcff-4edd-ac52-d6f83750f281"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate carcinogenic potential. However, a mouse micronucleus test and an Ames test were both negative for mutagenic effects.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b0dba2f1-32b2-4c16-a8d8-571e4a043c68"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_3a1c8344-50d5-4aea-a3da-aaff9f1dc9c3"></a><a name="section-7.6.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<p class="First"><span class="Underline">Pregnancy Category B. </span></p>
<p>Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ceftazidime for injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f7a1fb3e-e0c7-46f9-acce-a1f56d7fc2ff"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Ceftazidime is excreted in human milk in low concentrations. Caution should be exercised when ceftazidime is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f3519ebb-5dd9-459b-85a8-54bbbb93dee3"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">(see <span class="Bold"><a href="#i4i_dosage_admin_id_2a96dd57-bbfe-4d96-8576-af6ed0059c52">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_eadd10d2-85be-412c-a9eb-5e0d51fd142c"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 2,221 subjects who received ceftazidime in 11 clinical studies, 824 (37%) were 65 and older while 391 (18%) were 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><a href="#i4i_dosage_admin_id_2a96dd57-bbfe-4d96-8576-af6ed0059c52">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6903b1cb-746e-471e-bf4b-4945c2c47cc4"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Ceftazidime is generally well tolerated. The incidence of adverse reactions associated with the administration of ceftazidime was low in clinical trials. The most common were local reactions following IV injection and allergic and gastrointestinal reactions. Other adverse reactions were encountered infrequently. No disulfiram-like reactions were reported. </p>
<p>The following adverse effects from clinical trials were considered to be either related to ceftazidime therapy or were of uncertain etiology:</p>
<p><span class="Bold">Local Effects, </span>reported in fewer than 2% of patients, were <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> at the site of injection (1 in 69 patients).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>, </span>reported in 2% of patients, were <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Immediate reactions, generally manifested by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, occurred in 1 in 285 patients. <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have also been reported with cephalosporin antibiotics, including ceftazidime. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and/or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported very rarely.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Symptoms</span>, </span>reported in fewer than 2% of patients, were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1 in 78), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1 in 156), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1 in 500), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1 in 416). The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after treatment (see <span class="Bold"><a href="#i4i_warnings_id_472c30aa-e7af-46e8-97bf-e0647a877d4f">WARNINGS</a></span>).</p>
<p><span class="Bold">Central Nervous System Reactions </span>(fewer than 1%) included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported with several cephalosporins, including ceftazidime. In addition, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, and myoclonia have been reported in renally impaired patients treated with unadjusted dosing regimens of ceftazidime (see <span class="Bold"><a href="#i4i_precautions_general_id_2fbe65d8-c0b1-456b-aaaf-05b85ebbae03">PRECAUTIONS, General</a></span>).</p>
<p><span class="Bold">Less Frequent Adverse Events </span>(fewer than 1%) were <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> (including <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral thrush</span>) and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>. </p>
<p><span class="Bold">Hematologic: </span>Rare cases of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> have been reported.</p>
<p><span class="Bold">Laboratory Test Changes </span>noted during clinical trials with ceftazidime were transient and included: <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> (1 in 13), positive Coombs test without <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> (1 in 23), <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> (1 in 45), and slight elevations in one or more of the hepatic enzymes, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (1 in 16), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 in 19), and alkaline phosphatase (1 in 23). As with some other cephalosporins, transient elevations of blood urea, blood urea nitrogen, and/or serum creatinine were observed occasionally. Transient <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span> were seen very rarely.</p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact WG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_650080eb-b2ee-40db-a9e6-38ca2484bd92"></a><a name="section-9"></a><p></p>
<h1>POSTMARKETING EXPERIENCE WITH CEFTAZIDIME PRODUCTS</h1>
<p class="First">In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with ceftazidime and were reported spontaneously. For some of these events, data are insufficient to allow an estimate of incidence or to establish causation.</p>
<p><span class="Bold">General</span></p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, which, in rare instances, were severe (e.g., <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span>); <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection site.</p>
<p><span class="Bold">Hepatobiliary Tract</span></p>
<p><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. </p>
<p><span class="Bold">Renal and Genitourinary</span></p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>.</p>
<p><span class="Bold">Cephalosporin-Class Adverse Reactions</span></p>
<p>In addition to the adverse reactions listed above that have been observed in patients treated with ceftazidime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:</p>
<p><span class="Bold">Adverse Reactions</span></p>
<p><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p><span class="Bold">Altered Laboratory Tests</span></p>
<p>Prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, false-positive test for urinary glucose, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_0fd61602-a47a-4356-9df0-fe3234aac696"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Ceftazidime overdosage has occurred in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Reactions have included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Patients who receive an acute overdosage should be carefully observed and given supportive treatment. In the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, hemodialysis or peritoneal dialysis may aid in the removal of ceftazidime from the body.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2a96dd57-bbfe-4d96-8576-af6ed0059c52"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Dosage</span></p>
<p>The usual adult dosage is 1 gram administered intravenously every 8 to 12 hours. The dosage should be determined by the susceptibility of the causative organisms, the severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and the condition and renal function of the patient.</p>
<p>The guidelines for dosage of ceftazidime for injection are listed in <a href="#_RefID4B40B2D28A8740A8BBF5986524FF1F54">Table 5</a>. The following dosage schedule is recommended.</p>
<a name="_RefID4B40B2D28A8740A8BBF5986524FF1F54"></a><table width="100%">
<caption><span>Table 5. Recommended Dosage Schedule </span></caption>
<col width="53%">
<col width="33%">
<col width="14%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Although clinical improvement has been shown, bacteriologic cures cannot be expected in patients with <span class="product-label-link" type="condition" conceptid="4063381" conceptname="Chronic disease of respiratory system">chronic respiratory disease</span> and <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>The higher dose should be reserved for immunocompromised pediatric patients or pediatric patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> or <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Dose</span></p></td>
<td class="Rrule Toprule" align="center"><p class="First"><span class="Bold">Frequency</span></p></td>
</tr>
<tr><td class="Rrule" align="center" colspan="3"><p class="First"><span class="Bold">Adults</span></p></td></tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Usual recommended dosage</span></p></td>
<td align="center"><p class="First"><span class="Bold">1 gram IV</span></p></td>
<td class="Rrule" align="center"><p class="First"><span class="Bold">q8hr to 12hr</span></p></td>
</tr>
<tr>
<td align="center"><p class="First">Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span></p></td>
<td align="center"><p class="First">250 mg IV </p></td>
<td class="Rrule" align="center"><p class="First">q12hr</p></td>
</tr>
<tr>
<td align="center"><p class="First">Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span></p></td>
<td align="center"><p class="First">2 grams IV</p></td>
<td class="Rrule" align="center"><p class="First">q12hr</p></td>
</tr>
<tr>
<td align="center"><p class="First">Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span></p></td>
<td align="center"><p class="First">500 mg IV </p></td>
<td class="Rrule" align="center"><p class="First">q8hr to 12hr</p></td>
</tr>
<tr>
<td align="center">
<p class="First">Uncomplicated <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>; </p>
<p>mild skin and skin-structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></p>
</td>
<td align="center">
<p class="First">500 mg to 1 gram </p>
<p>IV</p>
</td>
<td class="Rrule" align="center"><p class="First">q8hr</p></td>
</tr>
<tr>
<td align="center">
<p class="First">Serious gynecologic and</p>
<p>intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span></p>
</td>
<td align="center"><p class="First">2 grams IV</p></td>
<td class="Rrule" align="center"><p class="First">q8hr</p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></p></td>
<td align="center"><p class="First">2 grams IV</p></td>
<td class="Rrule" align="center"><p class="First">q8hr</p></td>
</tr>
<tr>
<td align="center">
<p class="First">Very severe life-threatening </p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, especially in immunocompromised patients</p>
</td>
<td align="center"><p class="First">2 grams IV</p></td>
<td class="Rrule" align="center"><p class="First">q8hr</p></td>
</tr>
<tr>
<td align="center">
<p class="First"><span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">Lung infections</span> caused by <span class="Italics">Pseudomonas </span>spp. in patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> with </p>
<p>normal renal function<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
</td>
<td align="center"><p class="First">30 to 50 mg/kg IV to a maximum of 6 grams per day</p></td>
<td class="Rrule" align="center"><p class="First">q8hr</p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Neonates </span>(0 to 4 weeks)</p></td>
<td align="center"><p class="First">30 mg/kg IV</p></td>
<td class="Rrule" align="center"><p class="First">q12hr</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First"><span class="Bold">Infants and children </span>(1 month to 12 years)</p></td>
<td class="Botrule" align="center">
<p class="First">30 to 50 mg/kg IV to a</p>
<p>maximum of 6 grams per day<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">q8hr</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Impaired Hepatic Function</span></p>
<p>No adjustment in dosage is required for patients with hepatic dysfunction.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></p>
<p>Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (glomerular filtration rate [GFR] &lt;50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, an initial loading dose of 1 gram of ceftazidime may be given. An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in <a href="#_RefIDDBC1B4AE6D8C4CE1B7B960841EBC13CA">Table 6</a>.</p>
<p><span class="Bold">NOTE: IF THE DOSE RECOMMENDED IN TABLE 5 ABOVE IS LOWER THAN THAT RECOMMENDED FOR PATIENTS WITH <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">RENAL INSUFFICIENCY</span> AS OUTLINED IN TABLE 6, THE LOWER DOSE SHOULD BE USED.</span></p>
<a name="_RefIDDBC1B4AE6D8C4CE1B7B960841EBC13CA"></a><table width="100%">
<caption><span>Table 6. Recommended Maintenance Dosages of Ceftazidime for Injection in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> </span></caption>
<col width="23%">
<col width="35%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center">
<p class="First"><span class="Bold">Creatinine Clearance</span></p>
<p><span class="Bold">(mL/min)</span></p>
</td>
<td class="Toprule" align="center">
<p class="First"><span class="Bold">Recommended Unit </span></p>
<p><span class="Bold">Dose of Ceftazidime for Injection</span></p>
</td>
<td class="Rrule Toprule" align="center">
<p class="First"><span class="Bold">Frequency of </span></p>
<p><span class="Bold">Dosing</span></p>
</td>
</tr>
<tr>
<td align="center"><p class="First">50 to 31</p></td>
<td align="center"><p class="First">1 gram</p></td>
<td class="Rrule" align="center"><p class="First">q12hr</p></td>
</tr>
<tr>
<td align="center"><p class="First">30 to 16</p></td>
<td align="center"><p class="First">1 gram</p></td>
<td class="Rrule" align="center"><p class="First">q24hr</p></td>
</tr>
<tr>
<td align="center"><p class="First">15 to 6</p></td>
<td align="center"><p class="First">500 mg</p></td>
<td class="Rrule" align="center"><p class="First">q24hr</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First">&lt;5</p></td>
<td class="Botrule" align="center"><p class="First">500 mg</p></td>
<td class="Botrule Rrule" align="center"><p class="First">q48hr</p></td>
</tr>
</tbody>
</table>
<p>When only serum creatinine is available, the following formula (Cockcroftâ€™s equation)<span class="Sup">5</span> may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function:</p>
<p>Males: Creatinine clearance (mL/min) = <span class="Underline">Weight (kg) x (140 - age) __</span></p>
<p>                                                           72 x serum creatinine (mg/dL)</p>
<p>Females: 0.85 x male value</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> who would normally receive 6 grams of ceftazidime for injection daily were it not for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately. Further dosing should be determined by therapeutic monitoring, severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organism.</p>
<p>In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, and the dosing frequency should be reduced in cases of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period.</p>
<p>Ceftazidime for injection can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of ceftazidime for injection may be given, followed by 500 mg every 24 hours. In addition to IV use, ceftazidime for injection can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid.</p>
<p><span class="Bold">Note: </span>Generally ceftazidime for injection should be continued for 2 days after the signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> have disappeared, but in complicated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> longer therapy may be required.</p>
<p><span class="Bold">Administration</span></p>
<p>Ceftazidime for injection may be given intravenously. Intra-arterial administration should be avoided (see <span class="Bold"><a href="#i4i_precautions_id_03beb54d-c169-4418-b5d9-8056a58671a1">PRECAUTIONS</a></span>).</p>
<p><span class="Bold"><span class="Italics">Intravenous Administration: </span></span>The IV route is preferable for patients with bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, or other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or malignancy, particularly if <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present or pending.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_176bc21f-c96e-407c-9512-70fad244a757"></a><a name="section-11.1"></a><p></p>
<h2>Directions for Proper Use of a Pharmacy Bulk Package</h2>
<p class="First">Not for direct infusion. This Pharmacy Bulk Package is for use in a hospital pharmacy admixture service, only in a suitable work area, such as a laminar flow hood. Using aseptic technique, the container closure may be penetrated only one time using a suitable sterile dispensing set or transfer device that allows measured dispensing of the contents. Use of a syringe and needle is not recommended as it may cause leakage. The withdrawal of container contents should be accomplished without delay. However, should this not be possible, a maximum time of 4 HOURS from initial closure entry is permitted to complete fluid transfer operations. This time limit should begin with the introduction of the solvent or diluent into the Pharmacy Bulk Package. DISCARD ANY UNUSED PORTION AFTER 4 HOURS. NOT FOR DIRECT INFUSION. THIS PHARMACY BULK PACKAGE IS NOT INTENDED TO BE DISPENSED AS A UNIT.</p>
<p><span class="Bold"><span class="Italics">For IV infusion, </span></span>constitute the 6 g Pharmacy Bulk Package bottle with Sterile Water for Injection and add an appropriate quantity of the resulting solution to an IV container with one of the compatible IV fluids listed under the COMPATIBILITY AND STABILITY section.</p>
<p><span class="Bold"><span class="Italics">Intermittent IV infusion with a Y-type administration set </span></span>can be accomplished with compatible solutions. However, during infusion of a solution containing ceftazidime, it is desirable to discontinue the other solution.</p>
<p>Freezing solutions of ceftriaxone is not recommended.</p>
<a name="_RefIDBD3AA5CC7F31409DB26A4F036940CE0C"></a><table width="100%">
<caption><span>Table 7. Preparation of Solutions of Ceftazidime for Injection </span></caption>
<col width="22%">
<col width="23%">
<col width="25%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Size</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Amount of Diluent to be Added</span></p>
<p><span class="Bold">(mL)</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Approximate Available Volume</span></p>
<p><span class="Bold">(mL)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Approximate Ceftazidime Concentration</span></p>
<p><span class="Bold">(mg/mL)</span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">
<p class="First">Pharmacy bulk package bottle</p>
<p>6 grams</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule" align="center"><p class="First">30</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">200</p></td>
</tr>
</tbody>
</table>
<p>All Pharmacy Bulk Package bottles of ceftazidime for injection as supplied are under reduced pressure. When ceftazidime for injection is dissolved, <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> is released and a positive pressure develops. For ease of use please follow the recommended techniques of constitution described on the detachable Instructions for Constitution section of this insert. </p>
<p>Solutions of ceftazidime for injection, like those of most beta-lactam antibiotics, should not be added to solutions of aminoglycoside antibiotics because of potential interaction. </p>
<p>However, if concurrent therapy with ceftazidime for injection and an aminoglycoside is indicated, each of these antibiotics can be administered separately to the same patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5311fad6-28b4-4fbe-bc1f-264d2d93f666"></a><a name="section-12"></a><p></p>
<h1>COMPATIBILITY AND STABILITY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a8c093a8-fc00-4f36-8f5b-79378d18df0d"></a><a name="section-12.1"></a><p></p>
<h2>Intravenous</h2>
<p class="First">Ceftazidime for injection, when constituted as directed with Sterile Water for Injection should have the contents withdrawn within 4 hours. Solutions in 0.9% Sodium Chloride Injection in VIAFLEXÂ® small volume containers that are frozen immediately after constitution are stable for 3 months when stored at -20Â°C. Do not force thaw by immersion in water baths or by microwave irradiation. Once thawed, solutions should not be refrozen. Thawed solutions may be stored for up to 12 hours at room temperature or for 3 days in a refrigerator. </p>
<p>Ceftazidime is compatible with the more commonly used IV infusion fluids. Solutions at concentrations between 1 and 40 mg/mL in 0.9% Sodium Chloride Injection; 1/6 M Sodium Lactate Injection; 5% Dextrose Injection; 5% Dextrose and 0.225% Sodium Chloride Injection; 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.9% Sodium Chloride Injection; 10% Dextrose Injection; Ringerâ€™s Injection, USP; Lactated Ringerâ€™s Injection, USP; 10% Invert Sugar in Water for Injection; and NORMOSOLÂ®-M in 5% Dextrose Injection may be stored for up to 12 hours at room temperature or for 3 days if refrigerated.</p>
<p>Ceftazidime for injection is less stable in Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Injection than in other IV fluids. It is not recommended as a diluent. Solutions of ceftazidime for injection in 5% Dextrose Injection and 0.9% Sodium Chloride Injection are stable for at least 6 hours at room temperature in plastic tubing, drip chambers, and volume control devices of common IV infusion sets.</p>
<p>Ceftazidime at a concentration of 4 mg/mL has been found compatible for 12 hours at room temperature or for 3 days under refrigeration in 0.9% Sodium Chloride Injection or 5% Dextrose Injection when admixed with: cefuroxime sodium 3 mg/mL, heparin 10 or 50 U/mL, or potassium chloride 10 or 40 mEq/L.</p>
<p>Vancomycin solution exhibits a physical incompatibility when mixed with a number of drugs, including ceftazidime. The likelihood of precipitation with ceftazidime is dependent on the concentrations of vancomycin and ceftazidime present. It is therefore recommended, when both drugs are to be administered by intermittent IV infusion, that they be given separately, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> the IV lines (with 1 of the compatible IV fluids) between the administration of these 2 agents.</p>
<p><span class="Bold">Note: </span>Parenteral drug products should be inspected visually for particulate matter before administration whenever solution and container permit.</p>
<p>As with other cephalosporins, ceftazidime for injection powder, as well as solutions, tend to darken depending on storage conditions; within the stated recommendations, however, product potency is not adversely affected.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_897f6f2e-6417-491d-8c0b-9f363c97b2c2"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ceftazidime for injection, USP in the dry state should be stored at 20Âº to 25Â°C (68Âº to 77Â°F) [See USP controlled room temperature] and protected from light. Ceftazidime for injection, USP is a white to cream-colored crystalline powder supplied in Pharmacy Bulk Package Bottles as follows:</p>
<p>NDC 44567-237-06 6 g* Pharmacy Bulk Package Bottle (Carton of 6)</p>
<p>*Equivalent to anhydrous ceftazidime.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_09476d8a-e1c5-4f40-9210-5a206bdb1566"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition</span>. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012. </p>
<p>2. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement</span>, CLSI document M100-S24. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2014. </p>
<p>3. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard â€“ Eleventh Edition </span></p>
<p>CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012. </p>
<p>4. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eight Edition</span>. CLSI document M11-A8. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087 USA, 2012. </p>
<p>5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. <span class="Italics">Nephron. </span>1976;16:31-41. </p>
<p>Manufactured for:</p>
<p><span class="Bold">WG Critical Care, LLC </span></p>
<p>Paramus, NJ 07652</p>
<p>Made in Brazil</p>
<p>Brands listed are the trademarks of their respective owners.</p>
<p><br>Revised: October 2014</p>
<p>_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ </p>
<p>TEAR AWAY</p>
<p><span class="Bold">CEFTAZIDIME FOR INJECTION</span></p>
<p><span class="Bold">Instructions for Constitution</span></p>
<p><span class="Bold">Pharmacy Bulk Package: </span>6 g</p>
<p>1. Insert the syringe needle through the vial closure and inject 26 mL of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.</p>
<p>2. Shake to dissolve; a clear solution containing approximately 1 g of ceftazidime activity per 5 mL will be obtained in 1 to 2 minutes.</p>
<p>3. Insert a gas-relief needle through the vial closure to relieve the internal pressure. Remove the gas-relief needle before extracting any solution.</p>
<p><span class="Bold">Note: </span>To preserve product <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span>, it is important that a gas-relief needle is <span class="Italics">not </span>inserted through the vial closure before the product has dissolved.</p>
<p><br>Manufactured for:</p>
<p><span class="Bold">WG Critical Care, LLC </span></p>
<p>Paramus, NJ 07652</p>
<p>Made in Brazil</p>
<p>Revised: October 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_43ca6f11-d22d-4484-8963-2c84cc01095f"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 6 gram</h1>
<p class="First"><span class="Bold">NDC 44567-237-06</span></p>
<p><span class="Bold">CEFTAZIDIME FOR INJECTION, USP 6 GRAMS</span></p>
<p><span class="Bold">per Pharmacy Bulk Package</span></p>
<p><span class="Bold">PHARMACY BULK PACKAGE - NOT FOR DIRECT INFUSION</span></p>
<p><span class="Bold">CAUTION: NOT TO BE DISPENSED AS A UNIT</span></p>
<p><span class="Bold">For Intravenous Use</span></p>
<p><span class="Bold">FURTHER DILUTION IS REQUIRED</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id944"></a><img alt="6g vl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=22d6534c-4488-48a1-8d78-e2fb908259de&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFTAZIDIMEÂ 		
					</strong><br><span class="contentTableReg">ceftazidime injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44567-237</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFTAZIDIME</strong> (CEFTAZIDIME ANHYDROUS) </td>
<td class="formItem">CEFTAZIDIME ANHYDROUS</td>
<td class="formItem">6Â g Â inÂ 100Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44567-237-06</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062640</td>
<td class="formItem">01/31/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>WG Critical Care, LLC
							(829274633)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>250aa1a6-5e79-45c6-92b3-b14c558666ac</div>
<div>Set id: 22d6534c-4488-48a1-8d78-e2fb908259de</div>
<div>Version: 2</div>
<div>Effective Time: 20130119</div>
</div>
</div>Â <div class="DistributorName">WG Critical Care, LLC</div></p>
</body></html>
